당뇨병성 족부궤양 생물제제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Diabetic Foot Ulcer Biologics Market Growth & Trends:

The global diabetic foot ulcer biologics market size is anticipated to reach USD 3.11 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2025 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the growing competition among the market participants, rising research activities, the increasing number of clinical trials and studies along with increasing geriatric population. Moreover, the rising focus of industry players on expanding their presence is anticipated to propel market growth in the coming years.

For instance, a study from the National Library of Medicine in August 2022 reported that the risk of DFU increases with age. This correlation is closely linked to the longer duration of diabetes, the cumulative effects of hyperglycemia, and a higher prevalence of micro- and macrovascular complications. Therefore, the increasing prevalence of the geriatric population is expected to lead to a rise in diabetic foot ulcers. According to data published by the WHO in October 2024, the number of older people is estimated to increase significantly in the coming years. Below are some projections given by the WHO:

• By 2030, 1 in 6 people worldwide will be aged 60 or older, with the population in this age group growing from 1 billion in 2020 to 1.4 billion.
• By 2050, the worldwide population of individuals aged 60 and above is estimated to double, reaching 2.1 billion.
• The number of people aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million.

The increasing number of clinical trials is also expected to drive the market during the forecast period, attracting several companies to develop innovative treatments for diabetic foot ulcers. Various industry participants are actively engaged in clinical studies to bring novel biologics in the industry. For instance, in January 2025, RION, a clinical-stage regenerative medicine company, announced the completion of patient enrollment for its Phase 2 clinical trial of the Purified Exosome Product (PEP) in treating diabetic foot ulcers (DFUs). This prospective, multicenter, open-label study enrolled 59 patients across the U.S. It aims to assess the safety and efficacy of PEP when applied topically alongside standard wound care. PEP is a proprietary, lyophilized powder derived from human platelets that contains stabilized regenerative exosomes. These exosomes are engineered to enhance the body's natural healing processes by promoting cellular growth and reducing inflammation while also protecting vulnerable tissues-crucial elements for successful wound healing.

Diabetic Foot Ulcer Biologics Market Report Highlights:

• Based on product, the skin substitutes segment dominated the global diabetic foot ulcer biologics market in 2024. On the other hand, the tissue-engineered products segment is anticipated to grow at the fastest in the coming years.
• Based on indication, the neuro-ischemic ulcers segment held the largest revenue share of around 53.17% in the market in 2024. In contrast, the ischemic diabetic foot ulcer segment is expected to grow the fastest CAGR over the forecast period.
• Based on end use, the hospital segment dominated the market and accounted for a revenue share of 51.52% in 2024. On the other hand, ambulatory surgical centers segment is expected to grow the fastest over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Data Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Diabetic Foot Ulcer Biologics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of diabetic foot ulcer
    • 3.2.1.2. Technological advancements in biologics
    • 3.2.1.3. Rising geriatric population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of biologics products
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Rising distribution agreement for biologics
    • 3.2.3.2. Growing number of clinical trials
    • 3.2.3.3. Expansion of manufacturing and distribution facilities
    • 3.2.3.4. Expansion in emerging markets
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Intense Competition
• 3.3. Diabetic Foot Ulcer Biologics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Diabetic Foot Ulcer Biologics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 4.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.3.1. Skin Substitutes
    • 4.3.1.1. Skin-Substitutes market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.2. Biological
      • 4.3.1.2.1. Biological market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.3. Synthetic
      • 4.3.1.3.1. Synthetic market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.4. Bio-Synthetic
      • 4.3.1.4.1. Bio-Synthetic market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.2. Growth Factors
    • 4.3.2.1. Growth factors market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.3. Tissue-Engineered Products
    • 4.3.3.1. Tissue-engineered products market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Diabetic Foot Ulcer Biologics Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 5.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.3.1. Neuro-ischemic Ulcers
    • 5.3.1.1. Neuro-ischemic ulcers market estimates and forecast 2018 to 2030 (USD Million)
  • 5.3.2. Neuropathic Diabetic Foot Ulcer
    • 5.3.2.1. Neuropathic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
  • 5.3.3. Ischemic Diabetic Foot Ulcer
    • 5.3.3.1. Ischemic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Diabetic Foot Ulcer Biologics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 6.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Clinics
  • 6.5.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Ambulatory Surgical Centers (ASCs)
  • 6.6.1. Ambulatory Surgical Centers (ASCs) market estimates and forecast 2018 to 2030 (USD Million)
• 6.7. Long-Term Care Settings
  • 6.7.1. Long-term care settings market estimates and forecast 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Diabetic Foot Ulcer Biologics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada market estimates and forecasts, 2018 - 2030
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. Regulatory framework
    • 7.4.1.4. Reimbursement scenario
    • 7.4.1.5. UK market estimates and forecasts, 2018 - 2030
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. Germany market estimates and forecasts, 2018 - 2030
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. France market estimates and forecasts, 2018 - 2030
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. Italy market estimates and forecasts, 2018 - 2030
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Spain market estimates and forecasts, 2018 - 2030
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Norway market estimates and forecasts, 2018 - 2030
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement scenario
    • 7.5.1.5. Japan market estimates and forecasts, 2018 - 2030
  • 7.5.2. India
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. India market estimates and forecasts, 2018 - 2030
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. China market estimates and forecasts, 2018 - 2030
  • 7.5.4. South Korea
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. Australia market estimates and forecasts, 2018 - 2030
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement scenario
    • 7.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. UAE market estimates and forecasts, 2018 - 2030
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Organogenesis Holdings Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Tissue Regenix
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. BioTissue
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Integra LifeSciences
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. MIMEDX Group, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Convatec Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Coloplast Group (Kerecis)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Biocomposites
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Smith+Nephew, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Stedical Scientific, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Zimmer Biomet
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. GUNZE LIMITED
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives
• 8.4. Heat Map Analysis/ Company Market Position Analysis
• 8.5. Estimated Company Market Share Analysis, 2024
• 8.6. List of Other Key Market Players